New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?

The introduction of new metabolic tracers for positron emission tomography (PET) imaging is changing the landscape in the early biochemical recurrence of prostate cancer after radical prostatectomy (1).

[1]  H. G. van der Poel,et al.  Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature , 2019, BJU international.

[2]  M. Scorsetti,et al.  Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis , 2019, Strahlentherapie und Onkologie.

[3]  F. Montorsi,et al.  The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. , 2019, The Lancet. Oncology.

[4]  Roger Slavik,et al.  18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. , 2019, The Lancet. Oncology.

[5]  F. Alongi,et al.  (68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. , 2019, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[6]  Kirsten L. Greene,et al.  Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. , 2019, Urology.

[7]  J. Fütterer,et al.  A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. , 2019, European urology oncology.

[8]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[9]  N. Murray.  Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management , 2018, Biological Research.

[10]  Youssef A. Elnabawi,et al.  Clinical implications of PET/CT in prostate cancer management , 2018, Translational andrology and urology.

[11]  S. Fanti,et al.  68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  P. Wust,et al.  PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives , 2018, Radiation oncology.

[13]  F. Alongi,et al.  Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series , 2018, La radiologia medica.

[14]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  F. Alongi,et al.  Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT‐IGRT): A Mono‐institutional Report on Feasibility and Acute Toxicity , 2017, Clinical genitourinary cancer.

[16]  P. Stricker,et al.  Treatment Outcomes from 68Ga-PSMA PET/CT–Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET , 2017, Journal of Nuclear Medicine.

[17]  K. Pienta,et al.  A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) , 2017, BMC Cancer.

[18]  F. Lohr,et al.  Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study , 2017, British Journal of Cancer.

[19]  P. Stricker,et al.  68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment , 2016, BJU international.

[20]  F. Mottaghy,et al.  Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  F. Alongi,et al.  Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy , 2015, Clinical nuclear medicine.